A first genital herpes infection acquired close to delivery can pose a greater risk to a newborn than a recurrence. That difference is central to understanding herpes in pregnancy: the timing of infection, whether it is genuinely new, and whether symptoms are present during labour all help shape care. If you have new genital symptoms or think you may have been exposed, contact your maternity or sexual health clinician promptly.
Why A New Infection Near Delivery Is Different
After a first infection, your body develops antibodies to that herpes simplex virus (HSV) type. With a recurrence of the same type, those antibodies are already present and can offer the baby some protection. They also help limit the infection. If you acquire genital HSV late in pregnancy, there may not be enough time to develop and pass on those antibodies before birth; viral shedding can also be more likely around delivery.
“First episode” can need careful interpretation. Someone may have symptoms for the first time but already have antibodies to another HSV type. A clinician can assess the history and use testing to help distinguish a new infection from a recurrence. If a sore or blister is present, a swab test can identify HSV and its type. A negative result does not always rule out infection, particularly if a lesion is healing.
The higher concern is not a reason to assume a baby will be infected. It is a reason to get timely assessment, especially if a possible new infection occurs in the third trimester or near the due date. Tell your clinician when the exposure or symptoms began and whether you or a partner has had oral or genital herpes.
Herpes In Pregnancy: When Antivirals May Be Offered
Clinicians may offer suppressive antiviral treatment late in pregnancy to reduce recurrences and viral shedding near birth. Acyclovir is commonly discussed; valacyclovir may also be considered. Guidance summarized by the US Centers for Disease Control and Prevention (CDC) recommends suppressive treatment late in pregnancy for some patients with recurrent genital herpes. New Zealand guidance from 2012 recommends considering acyclovir from 36 weeks selectively, for example when a recurrence has occurred during that pregnancy, rather than routinely offering it to everyone with a history of herpes.
These medicines may lower the chance of an outbreak at delivery and reduce the need for a caesarean birth, but they do not guarantee that shedding or transmission will not occur. Acyclovir pregnancy data are reassuring: a registry report covering 1,234 exposed pregnancies did not find birth-defect rates or types that differed significantly from those in the general population. That is reassuring, not proof of zero risk. Older CDC guidance described more limited pregnancy data for valacyclovir and famciclovir. Your clinician can discuss the medicine, timing and uncertainties that apply to you.
How Lesions Or Warning Symptoms Can Affect Birth Planning
At the start of labour, tell the maternity team about any genital sores or warning symptoms such as pain, tingling or burning that may signal an outbreak. Guidance described by the CDC and by US and Canadian obstetric organizations supports caesarean delivery when genital lesions are present at labour; a 2026 review also identifies active lesions or prodromal symptoms as reasons to recommend caesarean birth. The aim is to reduce the baby’s contact with virus in genital secretions.
A history of herpes does not by itself settle the birth plan. The team will consider whether the infection is new or recurrent, when it began, and whether lesions or warning symptoms are present. Recommendations and local protocols can differ, and the regional guidance summarized here includes older documents. Ask your maternity team in advance how your local service handles a first infection late in pregnancy and symptoms at labour.
What The Newborn Team Needs To Know
Make sure the baby’s clinicians know about a genital herpes diagnosis, when symptoms or a possible first infection occurred, and whether lesions or warning symptoms were present during labour. A first infection late in pregnancy may warrant assessment by a paediatrician experienced in HSV, as recommended in New Zealand guidance. The baby’s assessment and any testing or treatment depend on the details of the exposure and birth; the material summarized here does not establish one universal testing plan for every newborn.
Suppressive treatment does not remove the need to share that history: New Zealand guidance advises the same postnatal surveillance whether or not suppressive acyclovir was used. If you are newly diagnosed, have possible exposure, or notice symptoms near your due date, seek prompt clinical advice rather than waiting for your next routine appointment.



















